Citigroup
MREO

Citigroup’s Mereo BioPharma MREO Stock Holding History

Citigroup’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-195,814
Closed -$81.6K – 6221
2025
Q4 		$81.6K Buy
+195,814
New +$373K ﹤0.01% 4406
2023
Q2 		– Sell
-1,130,650
Closed -$799K – 5673
2023
Q1 		$799K Buy
1,130,650
+1,129,103
+72,987% +$1.02M ﹤0.01% 2740
2022
Q4 		$1.16K Sell
1,547
-17,368
-92% -$14.3K ﹤0.01% 5369
2022
Q3 		$16K Buy
18,915
+17,044
+911% +$20.9K ﹤0.01% 4819
2022
Q2 		$2K Sell
1,871
-647
-26% -$501 ﹤0.01% 5900
2022
Q1 		$3K Sell
2,518
-857
-25% -$1.11K ﹤0.01% 5965
2021
Q4 		$5K Buy
+3,375
New +$6.75K ﹤0.01% 5661

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Citigroup's MREO Position: Q1 2026 in Review

Citigroup sold out of Mereo BioPharma (MREO) in Q1 2026, closing a stake of 195,814 shares — an estimated $81.6K sold.

Citigroup first reported a position in MREO in Q4 2021 and held it in 7 quarters. The position peaked at $799K in Q1 2023. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

  • Citigroup reported no remaining Mereo BioPharma position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 195,814 Mereo BioPharma shares in Q1 2026, an estimated $81.6K.
  • Citigroup first reported a position in Mereo BioPharma in Q4 2021 and held it in 7 quarters.
  • Citigroup's Mereo BioPharma position peaked at $799K in Q1 2023.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.